Yahoo
Tel Aviv - Delayed Quote ILA

Bio-View Ltd (BIOV.TA)

6,500.00 +509.00 (+8.50%)
At close: October 30 at 11:50:54 AM GMT+2
Chart Range Bar
Loading chart for BIOV.TA
  • Previous Close 5,991.00
  • Open 6,665.00
  • Bid --
  • Ask 6,634.00 x 648400
  • Day's Range 6,500.00 - 6,665.00
  • 52 Week Range 71.00 - 7,870.00
  • Volume 195
  • Avg. Volume 4,307
  • Market Cap (intraday) 9.034M
  • Beta (5Y Monthly) 0.00
  • PE Ratio (TTM) --
  • EPS (TTM) -96.00
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Mar 22, 2017
  • 1y Target Est --

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an automated imaging system that supports multiple applications; Encore, an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation that streamlines review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was incorporated in 1998 and is headquartered in Rehovot, Israel.

www.bioview.com

29

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

BIOV.TA
3,792.22%
TA-125 (^TA125.TA)
7.70%

1-Year Return

BIOV.TA
4,120.78%
TA-125 (^TA125.TA)
17.90%

3-Year Return

BIOV.TA
1,927.45%
TA-125 (^TA125.TA)
137.56%

5-Year Return

BIOV.TA
0.00%
TA-125 (^TA125.TA)
0.00%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -63.32%

  • Return on Assets (ttm)

    -13.29%

  • Return on Equity (ttm)

    -98.38%

  • Revenue (ttm)

    20.7M

  • Net Income Avi to Common (ttm)

    -13.11M

  • Diluted EPS (ttm)

    -96.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.17M

  • Total Debt/Equity (mrq)

    46.16%

  • Levered Free Cash Flow (ttm)

    3.61M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: